Cerebrolysin

At Verified Peptides, we want to lead with the single most important classification fact about Cerebrolysin: it is not a peptide in the sense used for the rest of this catalog. It is a standardized, enzymatically produced hydrolysate of purified porcine brain protein, manufactured by EVER Neuro Pharma (Austria, formerly marketed by EBEWE Pharma) under the designation FPF 1070. The finished preparation is a heterogeneous mixture consisting of approximately 75% free L-amino acids and approximately 25% low-molecular-weight bioactive peptide fragments, all below 10,000 Daltons — a genuinely different chemical category from the single defined-sequence peptides that make up most of this catalog.

This places Cerebrolysin in a similar broad category to Glandokort (also built on this site) — a natural, non-single-sequence biological extract — but with two important differences: Cerebrolysin is derived from mammalian brain tissue rather than adrenal tissue, and unlike Glandokort, it has a genuinely substantial, independently conducted (not confined to one originating institute) randomized controlled trial literature, described in detail below.

Cerebrolysin is approved as a pharmaceutical drug in more than 50 countries, including Russia, China, and several European and Asian markets, for indications including acute ischemic stroke, traumatic brain injury, vascular dementia, and Alzheimer's disease. It has never received FDA approval in the United States and, to our knowledge, does not hold a centralized EMA marketing authorization, despite being manufactured in Austria.

The broader concept behind Cerebrolysin — that a standardized extract of brain-tissue-derived peptides and amino acids could support neuronal health and recovery — reflects an older tradition in pharmaceutical development, predating the modern era of single-sequence recombinant and synthetic peptide drugs that dominates the rest of this catalog. Organ-extract-based preparations of this general kind have a long history in European and Russian pharmaceutical traditions specifically, and Cerebrolysin represents one of the most commercially successful and longest-marketed examples of this broader category still in active clinical use today.

At Verified Peptides, we think Cerebrolysin has one of the most substantial, genuinely independent (multi-institution, not single-lab) randomized controlled trial literatures of any compound in this catalog, and we want to describe it honestly, including its real controversies. The CARS trial (Muresanu et al., Stroke, 2016, PMID 26564102) was a prospective, randomized, placebo-controlled, double-blind, multicenter trial administering Cerebrolysin (30 mL/day) or placebo for 21 days beginning 24-72 hours after stroke onset, alongside standardized rehabilitation, and reported improved upper-extremity motor function and global recovery outcomes at day 90 in the Cerebrolysin group — a genuinely positive, well-designed randomized trial result.

However, the broader picture across the full trial literature is decidedly mixed, and we think researchers deserve this nuance rather than a cherry-picked positive result. A 2023 Cochrane Database Systematic Review (Ziganshina et al., PMID 37818733), pooling 7 randomized controlled trials and 1,773 participants with acute ischemic stroke, found moderate-certainty evidence that Cerebrolysin probably has no beneficial effect on preventing all-cause death, and found a potential increase in non-fatal serious adverse events associated with its use. This is a genuinely important, methodologically rigorous negative finding from the same overall body of stroke research that includes the positive CARS trial — the two are not contradictory so much as illustrative of how a single trial's positive result (CARS, focused on motor-function recovery) and a systematic review's broader safety/mortality focus (the Cochrane review) can tell different parts of the same story.

Separately, in dementia and cognitive-decline research, a meta-analysis of six randomized, double-blind, placebo-controlled trials reported Cerebrolysin was more effective than placebo for measures of cognitive function, but a Cochrane review of this literature rated the overall evidence quality as very low, citing small sample sizes and risk of bias across the included trials — again, a real, positive-leaning signal, but one explicitly rated as low-confidence by independent systematic review.

We want to be direct about what this overall picture means: Cerebrolysin has real regulatory approval in dozens of countries and a genuinely large, independently conducted trial literature — a different evidentiary situation from almost every other compound in this catalog — but that literature itself contains a mix of positive trial results and rigorous systematic reviews finding no mortality benefit and possible safety concerns, rated as low-to-moderate certainty evidence overall. At Verified Peptides, we sell research-grade Cerebrolysin exclusively for laboratory research, and we think researchers should engage directly with this genuinely mixed evidence base rather than relying on either uncritically positive or uncritically dismissive summaries of it.

Cerebrolysin's approval in over 50 countries but absence from FDA and (to our knowledge) centralized EMA approval reflects a broader pattern seen with several natural extract-based pharmaceutical products: different regulatory systems apply different evidentiary standards and different levels of tolerance for complex, incompletely characterized natural mixtures as approvable drugs, and a product's approval status in one regulatory system does not automatically transfer to or predict its approval status in another.

Because Cerebrolysin's exact detailed peptide composition is proprietary manufacturing information, independent researchers attempting to characterize its full composition have had to use analytical chemistry techniques (such as mass spectrometry profiling) to identify at least some of its constituent peptide fragments, an active area of independent analytical research distinct from the clinical trial literature — one referenced comparative composition study specifically examined how Cerebrolysin's biological activity and composition compare against other peptide preparations in the same general product category.

The 2023 Cochrane review's finding of a potential increase in non-fatal serious adverse events alongside no mortality benefit is a genuinely important, if sobering, piece of information that researchers should weigh carefully — it does not mean Cerebrolysin is unsafe in an absolute sense, but it does mean the highest-quality available evidence does not support a clear net clinical benefit for acute ischemic stroke specifically, even though other individual trials (like CARS) have shown positive results on different, more specific outcome measures (motor recovery rather than mortality).

Cerebrolysin's decades-long clinical history (the compound and its FPF 1070 designation predate much of the modern single-sequence synthetic peptide research reflected elsewhere in this catalog) makes it one of the longest continuously marketed compounds in this entire build project, illustrating how natural biological extracts and modern single-sequence synthetic peptides can have very different development timelines and regulatory histories despite sometimes being discussed in the same general "research peptide" commercial space.

At Verified Peptides, we require documentation of manufacturing and quality-control standards for research-grade Cerebrolysin we offer, since it is a natural, standardized biological extract rather than a synthesized single compound. Because Cerebrolysin is inherently a heterogeneous mixture — a defined ratio of free amino acids to low-molecular-weight peptide fragments rather than one molecule — standard single-compound purity metrics such as HPLC purity percentage against one target molecular weight do not directly apply the way they do for a synthesized peptide.

We source exclusively from manufacturers operating under quality-controlled extraction and standardization systems, and we recommend researchers request whatever batch documentation is available and treat any specific compositional consistency claims with appropriate caution given the inherent complexity of fully characterizing a heterogeneous natural peptide/amino-acid mixture compared to a single defined-sequence compound.

Cerebrolysin solution is typically supplied ready-to-use (as a clear, sterile solution rather than lyophilized powder in its standard pharmaceutical formulation) and should be stored according to manufacturer guidance, generally protected from light at controlled room temperature or refrigerated depending on the specific formulation. At Verified Peptides, we ship material with packaging appropriate to preserve stability in transit.

Because Cerebrolysin is a complex mixture of free amino acids and peptide fragments rather than a single molecular species, its overall stability profile reflects the combined behavior of many different components rather than one well-characterized degradation pathway. Researchers should follow the specific storage guidance provided with each lot's documentation.